Matisse Capital Verona Pharma PLC Transaction History
Matisse Capital
- $205 Million
- Q3 2024
A detailed history of Matisse Capital transactions in Verona Pharma PLC stock. As of the latest transaction made, Matisse Capital holds 23,400 shares of VRNA stock, worth $834,443. This represents 0.33% of its overall portfolio holdings.
Number of Shares
23,400
Previous 34,400
31.98%
Holding current value
$834,443
Previous $497,000
35.41%
% of portfolio
0.33%
Previous 0.25%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
166Shares Held
68.7MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$225 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$199 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$179 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$150 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$127 Million14.95% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $2.17B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...